Commons Sense

House of Commons · Written Ministerial Statement

Prostate Cancer Screening

02 June 2026 · Department of Health and Social Care

Proposed by Sharon Hodgson Lab Washington and Sunderland West

NHS

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • The Government will introduce a targeted prostate cancer screening programme for men with a known BRCA2 gene variant and relevant family history.
  • The programme will use an IT call and recall system and is set to begin in 2027.
  • Over 20 million will be invested to expand research and improve treatment for prostate cancer.

Issue summary

The Minister is announcing the introduction of a targeted prostate cancer screening programme for men with a known BRCA2 gene variant and relevant family history.

Action requested

The Government will roll out a targeted prostate cancer screening programme using an IT call and recall system starting in 2027, invest over £20 million to expand research and improve treatment, and update guidance for GPs and the public. Additionally, they are hosting a roundtable with local community organisations to boost engagement.

Key facts

  • The targeted prostate cancer screening programme will begin roll-out in 2027.
  • Men aged 45 to 61 with a known BRCA2 gene variant and relevant family history will be offered PSA screening every two years.
  • The Government is investing over £20 million, including up to an additional £18 million to the TRANSFORM trial and up to £2.8 million in focal therapy.
  • Community level research for all eligible Black men between 45 and 74 years will be invited to participate in stage 2 of the TRANSFORM trial.
▸ Assessment & feedback
Summary accuracy